Auris Medical Holding has set the pricing terms of its IPO. It plans on selling 6.9 million shares at $10 to $12 per share. The company will trade the stock on the NASDAQ under the ticker symbol “EARS.” Jefferies and Leerink Partners are serving as lead underwriters. Headquartered in Zug, Switzerland, Auris Medical is a biopharmaceutical company focused on otolaryngology. Its backers include Sofinnova Venture Partners, Sofinnova Capital, Adamant Global Generika Funds and Idinvest Partners
Auris Medical Holding AG announced today that it has commenced the underwritten initial public offering of 6,900,000 of its common shares (Offering) pursuant to a registration statement on Form F-1 with the Securities and Exchange Commission (SEC). In connection with the Offering, the Company intends to grant the underwriters the option to purchase up to 1,035,000 additional common shares. The estimated price range for the initial public offering is $10.00 to $12.00 per common share. Auris Medical Holding AG has applied to list its common shares on the Nasdaq Global Select Market under the ticker symbol “EARS”.
Jefferies LLC and Leerink Partners LLC are acting as joint book-running managers in the proposed offering. JMP Securities LLC and Needham & Company, LLC are acting as co-managers in the proposed offering.
The proposed offering will be made only by means of a prospectus. When available, copies of the preliminary prospectus related to the offering may be obtained from: Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, 2nd Floor, New York, NY 10022, by emailing [email protected], or by calling (877) 547-6340 or Leerink Partners LLC, Attention: Syndicate Department, One Federal Street, 37th Floor, Boston, MA 02110 or by email at [email protected], or by calling (800) 808-7525.
A registration statement on Form F-1 relating to the proposed offering has been filed with the SEC but has not yet become effective. The common shares to be registered may not be sold nor may offers to buy be accepted prior to the time when the registration statement becomes effective. Copies of the registration statement can be accessed through the SEC’s website at www.sec.gov. This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
About Auris Medical
Auris Medical is a Swiss biopharmaceutical company dedicated to developing therapeutics that address important unmet medical needs in otolaryngology. The Company is currently focusing on the development of treatments for acute inner ear tinnitus (AM-101) and for acute inner ear hearing loss (AM-111) by way of intratympanic injection with biocompatible gel formulations. In addition, Auris Medical is pursuing early-stage research and development projects. The Company was founded in 2003 and is headquartered in Zug, Switzerland.
Take your pick!
- Buyouts delivers exclusive news and analysis about private equity deals, fundraising, top-quartile managers and more. Get your FREE trial or subscribe now.
- VC Journal provides exclusive news and analysis about venture capital deals, fundraising, top-quartile investors and more. Get your FREE trial or subscribe now.